Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Rating of "Buy" by Brokerages

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) have earned an average rating of "Buy" from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $32.83.

CPRX has been the topic of several research reports. HC Wainwright reissued a "buy" rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Wall Street Zen raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Robert W. Baird raised their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday, March 3rd. Finally, Stephens reissued an "overweight" rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th.

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock opened at $22.07 on Wednesday. Catalyst Pharmaceuticals has a 1 year low of $14.75 and a 1 year high of $26.58. The company has a market capitalization of $2.69 billion, a P/E ratio of 14.06, a PEG ratio of 0.90 and a beta of 0.72. The company's fifty day moving average is $23.91 and its two-hundred day moving average is $22.90.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Preethi Sundaram sold 1,600 shares of the firm's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total value of $42,272.00. Following the completion of the sale, the insider now owns 41,081 shares in the company, valued at $1,085,360.02. This trade represents a 3.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Gary Ingenito sold 200,000 shares of the firm's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $23.68, for a total transaction of $4,736,000.00. Following the completion of the sale, the insider now owns 68,873 shares of the company's stock, valued at $1,630,912.64. This trade represents a 74.38% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 247,924 shares of company stock worth $5,879,369. Company insiders own 10.40% of the company's stock.

Institutional Trading of Catalyst Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Steward Partners Investment Advisory LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at about $27,000. Park Square Financial Group LLC acquired a new position in Catalyst Pharmaceuticals during the fourth quarter worth about $29,000. Sound Income Strategies LLC acquired a new position in Catalyst Pharmaceuticals during the first quarter worth about $64,000. Farther Finance Advisors LLC raised its position in Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after acquiring an additional 1,495 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in Catalyst Pharmaceuticals by 26.2% during the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock worth $68,000 after acquiring an additional 579 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company's stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.